Full Text:

 

Ǵм Vol.24_No.2 Suppl. P.S642-646, Dec. 2007

Case Report

Enoxaparin Induced Fatal Retroperitoneal Hematoma in Elderly Patient with Acute Coronary Syndrome Case Report

Sang-Hee Lee, Jong-Seon Park, Woong Kim, Geu-Ru Hong, Dong-Gu Shin, Young-Jo Kim, Bong-Sub Shim
Division of Cardiology, Department of Internal Medicine, Yeungnam University hospital, Daegu, Korea
åڣ, 뱸 5 317-1, б ǰ б
Tel: (053) 620-3837, Fax: (053) 620-8386
E-mail: jspark@med.yu.ac.kr

December 30, 2007

Abstract

Anticoagulation and antiplatelet therapy became a cornerstone of the primary treatment strategy in the case of acute coronary syndrome patients which planned to receive medical treatment or percutaneous coronary intervention. The anticoagulation regimen is unfractionated heparins and low molecular weight heparins enoxaparin. Despite of some debates, enoxaparin has replaced unfractionated heparins recently due to its demonstrated advantages. When we encountered acute coronary syndrome patients without contraindication for enoxaparin, it tends to be administered with no hesitation. However, a few patients treated with enoxaparin could be suffered from bleeding complication. Also, in case of bleeding into the retroperitoneal space, the result can be fatal. We report a patient who developed a fatal retroperitoneal hematoma during enoxaparin treatment for acute coronary syndrome.

Key Words: Enoxaparin, Acute Coronary Syndrome, Retroperitoneal Hematoma

References

1. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, et al. Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfrac- tionated Heparin for Antithrombin Therapy in Non?ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview. JAMA 2004 Jul 7;292(1):89-96.

2. Jeong TK, Jeong GH, Park BS, Ma SK, Kim SW, Kim NH, et al. Dalteparin-sodium associated retroperitoneal hematoma in a patient with diabetic nephropathy. Korean J Med 2003 64:322-7.

3. Collet JP, Montalescot G, Fine E, Golmard JL, Dalby M, Choussat R, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003 Jan 1;41(1):8-14.

4. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003 Jul;146(1):33-41.

5. A Vaya, Y Mira, J Aznar. Enoxaparin-related fatal spontaneous retroperitoneal hematoma in the elderly. Thromb Res 2003 Apr 15;110(1): 69-71.

6. The SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004 Jul 7;292(1):45-54.

7. Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: Results from the A phase of the A-to-Z trial. Eur Heart J 2004 Oct 25(19):1688-94.

8. Cadroy Y, Pourrat J, Baladre MF, Saivin S, Houin G, Montastruc JL, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991 Aug 1;63(3):385-90.

9. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. N Engl J Med 2006 Apr 6;354(14): 1477-88.

10. Gonzalez C, Penado S, Llata L, Valero C, Riancho JA. The clinical spectrum of retroperitoneal hematoma in anticoagulated patients. Medicine 2003 Jul 82(4):257-62.